Date of Award
Spring 2022
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Stephanie Pillai, MPAS, PA-C
Abstract
Type 2 diabetes is a common disease in the United States that can result in life-threatening cardiac, vascular, and/or renal complications. The treatment of type 2 diabetes includes but is not limited to exercise, diet, multi-disciplinary approaches, and pharmaceuticals. Metformin is the first line pharmaceutical for newly diagnosed type 2 diabetes, however patients may be unable to tolerate metformin. With more than seven different antihyperglycemic drug classes and over twenty antihyperglycemic drugs, clinicians may have difficulty choosing the best agent for patients when metformin is not tolerated. This article compares common anti-hyperglycemic pharmaceutical agents and their drug classes, focusing on the risk for hypoglycemia, efficacy of glycated hemoglobin (HbA1c) reduction, cost, cardiorenal protection, and weight changes. By comparing these factors, the article aims to equip healthcare providers with basic knowledge when choosing an anti-hyperglycemic agent for patients.
Recommended Citation
Ogino, Rena, "Initial Antihyperglycemic Options for Populations with Type 2 Diabetes who Cannot Take Metformin" (2022). Capstone Showcase. 27.
https://scholarworks.arcadia.edu/showcase/2022/pa/27
Included in
Endocrinology, Diabetes, and Metabolism Commons, Family Medicine Commons, Internal Medicine Commons, Primary Care Commons
Initial Antihyperglycemic Options for Populations with Type 2 Diabetes who Cannot Take Metformin
Type 2 diabetes is a common disease in the United States that can result in life-threatening cardiac, vascular, and/or renal complications. The treatment of type 2 diabetes includes but is not limited to exercise, diet, multi-disciplinary approaches, and pharmaceuticals. Metformin is the first line pharmaceutical for newly diagnosed type 2 diabetes, however patients may be unable to tolerate metformin. With more than seven different antihyperglycemic drug classes and over twenty antihyperglycemic drugs, clinicians may have difficulty choosing the best agent for patients when metformin is not tolerated. This article compares common anti-hyperglycemic pharmaceutical agents and their drug classes, focusing on the risk for hypoglycemia, efficacy of glycated hemoglobin (HbA1c) reduction, cost, cardiorenal protection, and weight changes. By comparing these factors, the article aims to equip healthcare providers with basic knowledge when choosing an anti-hyperglycemic agent for patients.